Breaking News Instant updates and real-time market news.

VHC

VirnetX

, AAPL

Apple

$113.05

0.87 (0.78%)

09:25
10/03/16
10/03
09:25
10/03/16
09:25

VirnetX up 60% to $4.90 after patent infringement victory against Apple

VHC

VirnetX

AAPL

Apple

$113.05

0.87 (0.78%)

  • 25

    Oct

  • 13

    Mar

VHC VirnetX

02/04/16
COWN
02/04/16
NO CHANGE
Target $36
COWN
Outperform
VirnetX win in Apple case should help in signing licenses, says Cowen
Cowen analyst Robert Stone said the jury award in favor of VirnetX (VHC) in its patent fight with Apple (AAPL) should aid the company in signing licenses with others. Stone, who thinks talks have been underway with Android OEMs and infrastructure players and expects that the "first couple of contracts" could be signed in the coming months, keeps an Outperform rating and $36 price target on VirnetX shares.
AAPL Apple
$113.05

0.87 (0.78%)

10/03/16
PIPR
10/03/16
NO CHANGE
Target $151
PIPR
Overweight
Apple checks show iPhone 7 inventory still constrained, says Piper Jaffray
Piper Jaffray analyst Gene Munster said his checks of 134 Apple Stores in the U.S. showed that iPhone 7 and iPhone 7 Plus inventory levels are improved, but still constrained, and that supply appears even tighter in China. The limited supply of the iPhone 7 Plus should bode well for the December quarter outlook, adds Munster, who keeps an Overweight rating and $151 price target on Apple shares.
09/30/16
SBSH
09/30/16
NO CHANGE
Target $130
SBSH
Buy
Apple price target raised to $130 from $120 at Citi
Citi analyst Jim Suva raised his price target for Apple shares to $130 from $120 and keeps a Buy rating on the name. The stock closed yesterday down $1.77 to $112.18. U.S., Canada, European and Asian store checks indicate iPhone 7 demand at launch appears strong, Suva tells investors in a research note. Supply remains a limiting factor with many stores having received very limited supply of the iPhone 7 and in some cases only to suffice demand from preorders, the analyst adds. Suva raised his iPhone estimate for the December quarter to 79.4M units, above the consensus of 75M units.
09/29/16
LEHM
09/29/16
NO CHANGE
Target $61
LEHM
Overweight
Western Digital is a new Top Pick in IT Hardware at Barclays
Barclays analyst Mark Moskowitz recommends investors build positions in Western Digital (WDC) and named it his new Top Pick in IT Hardware, removing Apple (AAPL). Western Digital issued a positive September quarter financial update citing a favorable mix in both HDD and SSD, and particularly good pricing conditions in NAND flash, the analyst wrote. Moskowitz believes the company's commentary is positive for investor sentiment and added it to the top spot given improving end markets, reduced industry manufacturing capacity, and potential for further operational synergies. He recommends investors build or add positions in Western Digital as gross margins should trend upward in the near- to mid-term. Moskowitz rates Western Digital an Overweight with a $61 price target on shares.
09/29/16
LEHM
09/29/16
NO CHANGE
Target $114
LEHM
Overweight
Barclays removes Apple as Top Pick after trimming global smartphone forecast
Barclays analyst Mark Moskowitz removed the firm's Top Pick designation on Apple (AAPL) shares after the firm trimmed its 2016 smartphone revenue and unit growth estimates, saying that the firm's research is not pointing to any major improvement in smartphone units beyond initial channel fill for the new iPhones and Samsung (SSNLF) Galaxy products. The firm now estimates a decline of 2.9% in smartphone revenue and growth of 2.6% in smartphone units, versus its prior forecast for a revenue decline of 0.7% and unit growth of 3.7% in 2016. Moskowitz, who thinks Apple shares may see near-term choppiness after their recent run-up, keeps an Overweight rating on the stock but lowered his price target to $114 from $115.

TODAY'S FREE FLY STORIES

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ABBV

AbbVie

$59.43

0.27 (0.46%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

18:29
12/04/16
12/04
18:29
12/04/16
18:29
Hot Stocks
AbbVie reports five-year IMBRUVICA data, updated RESONATE-2 data »

AbbVie (ABBV) announced…

ABBV

AbbVie

$59.43

0.27 (0.46%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

18:17
12/04/16
12/04
18:17
12/04/16
18:17
Hot Stocks
Celgene, Dana-Farber, U of Arkansas form Myeloma Genome Project »

Celgene, Dana-Farber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

ARQL

ArQule

$1.37

-0.01 (-0.72%)

18:12
12/04/16
12/04
18:12
12/04/16
18:12
Hot Stocks
ArQule reports data presentation on ARQ 092 in sickle cell disease »

ArQule announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.50

-0.44 (-0.44%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

18:08
12/04/16
12/04
18:08
12/04/16
18:08
Hot Stocks
Box Office Battle: 'Moana,' 'Fantastic Beasts' win post-Thanksgiving weekend »

Disney's (DIS)…

DIS

Disney

$98.50

-0.44 (-0.44%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

SNE

Sony

$28.06

-0.16 (-0.57%)

FOX

21st Century Fox

$27.37

-0.71 (-2.53%)

FOXA

21st Century Fox

$27.40

-0.8 (-2.84%)

LGF

Lionsgate

$22.72

0.02 (0.09%)

CMCSA

Comcast

$68.78

-1.08 (-1.55%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

16:04
12/04/16
12/04
16:04
12/04/16
16:04
Hot Stocks
Alnylam reports interim Phase 1 data on fitusiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.